Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 10, Number 3, March 2018, pages 178-181


Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)

Figure

Figure 1.
Figure 1. Kaplan-Meier curves for overall survival: molGPA 4.0 (3.5 - 4 points, n = 6) vs. molGPA 3.0 (2.5 - 3 points, n = 7) vs. molGPA 2.0 (1.5 - 2 points, n = 23) and molGPA 1.0 (0 - 1 points, n = 33), P = 0.0001 (pooled over all strata).

Tables

Table 1. Calculation of the Prognostic Score, as Reported by Sperduto et al [12]
 
Parameter0 points0.5 points1 point
Age ≥ 70 yearsx
Age < 70 yearsx
KPS ≤ 70x
KPS 80x
KPS 90 - 100x
Presence of extracranial metastasesx
Absence of extracranial metastasesx
More than four brain metastasesx
2 - 4 brain metastasesx
1 brain metastasisx
Negative/unknown BRAF statusx
Positive BRAF statusx

 

Table 2. Pretreatment Characteristics of All 69 Patients Included in This Study
 
ParameterNumberPercentMedian overall survival in monthsP-value (log-rank test)
KPS: Karnofsky performance status; WBRT: whole-brain radiotherapy.
Female gender30435.9
Male gender39574.80.38
Extracranial metastases absent121712.1
Extracranial metastases present57833.70.003
KPS ≤ 7025362.0
KPS 8018265.8
KPS 90 - 100263811.80.0001
Single brain metastasis111612.1
2 - 4 brain metastases25367.9
> 4 brain metastases33482.30.0001
Age < 70 years50727.3
Age ≥ 70 years19282.70.001
BRAF positive9-7.3
BRAF negative12-2.10.08
WBRT48703.1
Surgery/stereotactic RT213012.10.0001

 

Table 3. Comparison of the Median Survival Results in Months With Those Reported by Sperduto et al [11, 12]
 
StudynAll patientsDS-GPA unfavorableDS-GPA intermediateDS-GPA second bestDS-GPA best
DS-GPA: diagnosis-specific graded prognostic assessment score (in this case limited to patients with malignant melanoma).
Sperduto et al [11]4836.73.44.78.813.2
Nieder et al [3]513.73.13.77.512.7
Sperduto et al [12]8239.84.98.315.834.1
Present study695.42.17.811.818.0